HealthMore in Health→
GSK Acquires Nuvalent for $10.6B to Boost Targeted Cancer Drug Pipeline
Key Takeaways
- GSK to acquire Nuvalent for $10.6 billion.
- Nuvalent develops targeted cancer drugs zidesamtinib and neladalkib.
- Deal expected to close in Q3 2026.
- Acquisition strengthens GSK's oncology pipeline.
DE
DT Editorial Team··via statnews.com